Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 231

1.

Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening.

Akbari A, Vanden Broeck D, Benoy I, Padalko E, Bogers J, Arbyn M.

Virol J. 2018 Oct 29;15(1):166. doi: 10.1186/s12985-018-1076-6.

2.

The legal framework for European cervical cancer screening programmes.

Májek O, Anttila A, Arbyn M, van Veen EB, Engesæter B, Lönnberg S.

Eur J Public Health. 2018 Sep 27. doi: 10.1093/eurpub/cky200. [Epub ahead of print]

PMID:
30265313
3.

The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium.

Bonde J, Ejegod DM, Cuschieri K, Dillner J, Heideman DAM, Quint W, Pavon Ribas MA, Padalko E, Christiansen IK, Xu L, Arbyn M.

J Clin Virol. 2018 Nov;108:64-71. doi: 10.1016/j.jcv.2018.09.012. Epub 2018 Sep 17.

4.

Validation of EUROArray HPV test using the VALGENT framework.

Viti J, Poljak M, Oštrbenk A, Bhatia R, Alcañiz Boada E, Cornall AM, Cuschieri K, Garland S, Xu L, Arbyn M.

J Clin Virol. 2018 Nov;108:38-42. doi: 10.1016/j.jcv.2018.09.005. Epub 2018 Sep 10.

PMID:
30223253
5.

Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.

Oštrbenk A, Xu L, Arbyn M, Poljak M.

J Clin Microbiol. 2018 Oct 25;56(11). pii: e01176-18. doi: 10.1128/JCM.01176-18. Print 2018 Nov.

PMID:
30209184
6.

Clinical Evaluation of INNO-LiPA HPV Genotyping EXTRA II Assay Using the VALGENT Framework.

Xu L, Padalko E, Oštrbenk A, Poljak M, Arbyn M.

Int J Mol Sci. 2018 Sep 11;19(9). pii: E2704. doi: 10.3390/ijms19092704.

7.

VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples.

Arbyn M, Peeters E, Benoy I, Vanden Broeck D, Bogers J, De Sutter P, Donders G, Tjalma W, Weyers S, Cuschieri K, Poljak M, Bonde J, Cocuzza C, Zhao FH, Van Keer S, Vorsters A.

J Clin Virol. 2018 Oct;107:52-56. doi: 10.1016/j.jcv.2018.08.006. Epub 2018 Aug 22.

PMID:
30195193
8.

Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis.

Clarke MA, Long BJ, Del Mar Morillo A, Arbyn M, Bakkum-Gamez JN, Wentzensen N.

JAMA Intern Med. 2018 Sep 1;178(9):1210-1222. doi: 10.1001/jamainternmed.2018.2820.

PMID:
30083701
9.

Beta-binomial analysis of variance model for network meta-analysis of diagnostic test accuracy data.

N Nyaga V, Arbyn M, Aerts M.

Stat Methods Med Res. 2018 Aug;27(8):2554-2566. doi: 10.1177/0962280216682532. Epub 2016 Dec 14.

PMID:
29984635
10.

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.

Arbyn M, Xu L, Simoens C, Martin-Hirsch PP.

Cochrane Database Syst Rev. 2018 May 9;5:CD009069. doi: 10.1002/14651858.CD009069.pub3. Review.

PMID:
29740819
11.

Human papillomavirus vaccination coverage in Luxembourg - Implications of lowering and restricting target age groups.

Latsuzbaia A, Arbyn M, Weyers S, Mossong J.

Vaccine. 2018 Apr 25;36(18):2411-2416. doi: 10.1016/j.vaccine.2018.03.054. Epub 2018 Mar 27.

12.

Complete Genome Sequence of a Novel Human Gammapapillomavirus Isolated from a Cervical Swab in Luxembourg.

Latsuzbaia A, Arbyn M, Dutta S, Fischer M, Gheit T, Tapp J, Tommasino M, Weyers S, Mossong J.

Genome Announc. 2018 Mar 15;6(11). pii: e00114-18. doi: 10.1128/genomeA.00114-18.

13.

Assessing factors associated with long-term work disability after cancer in Belgium: a population-based cohort study using competing risks analysis with a 7-year follow-up.

Kiasuwa Mbengi RL, Nicolaie AM, Goetghebeur E, Otter R, Mortelmans K, Missinnne S, Arbyn M, Bouland C, de Brouwer C.

BMJ Open. 2018 Feb 17;8(2):e014094. doi: 10.1136/bmjopen-2016-014094.

14.

Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs.

Cuschieri K, Ronco G, Lorincz A, Smith L, Ogilvie G, Mirabello L, Carozzi F, Cubie H, Wentzensen N, Snijders P, Arbyn M, Monsonego J, Franceschi S.

Int J Cancer. 2018 Aug 15;143(4):735-745. doi: 10.1002/ijc.31261. Epub 2018 Feb 8. Review.

PMID:
29341110
15.

Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.

Xu L, Oštrbenk A, Poljak M, Arbyn M.

J Clin Virol. 2018 Jan;98:37-42. doi: 10.1016/j.jcv.2017.12.001. Epub 2017 Dec 6.

PMID:
29241150
16.

Overcoming barriers in HPV vaccination and screening programs.

Vorsters A, Arbyn M, Baay M, Bosch X, de Sanjosé S, Hanley S, Karafillakis E, Lopalco PL, Pollock KG, Yarwood J, Van Damme P.

Papillomavirus Res. 2017 Dec;4:45-53. doi: 10.1016/j.pvr.2017.07.001. Epub 2017 Jul 20.

17.

Cervical morbidity in Alsace, France: results from a regional organized cervical cancer screening program.

Baldauf JJ, Fender M, Bergeron C, Marrer E, Velten M, Pradat P, Arbyn M.

Eur J Cancer Prev. 2017 Nov 13. doi: 10.1097/CEJ.0000000000000415. [Epub ahead of print]

PMID:
29135538
18.

Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis.

Arbyn M, Redman CWE, Verdoodt F, Kyrgiou M, Tzafetas M, Ghaem-Maghami S, Petry KU, Leeson S, Bergeron C, Nieminen P, Gondry J, Reich O, Moss EL.

Lancet Oncol. 2017 Dec;18(12):1665-1679. doi: 10.1016/S1470-2045(17)30700-3. Epub 2017 Nov 7. Review.

19.

Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease.

Kyrgiou M, Athanasiou A, Kalliala IEJ, Paraskevaidi M, Mitra A, Martin-Hirsch PP, Arbyn M, Bennett P, Paraskevaidis E.

Cochrane Database Syst Rev. 2017 Nov 2;11:CD012847. doi: 10.1002/14651858.CD012847. Review.

PMID:
29095502
20.

Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.

Polman NJ, Oštrbenk A, Xu L, Snijders PJF, Meijer CJLM, Poljak M, Heideman DAM, Arbyn M.

J Clin Microbiol. 2017 Dec;55(12):3544-3551. doi: 10.1128/JCM.01282-17. Epub 2017 Oct 11.

21.

Defining Optimal Triage Strategies for hrHPV Screen-Positive Women-An Evaluation of HPV 16/18 Genotyping, Cytology, and p16/Ki-67 Cytoimmunochemistry.

Stanczuk GA, Baxter GJ, Currie H, Forson W, Lawrence JR, Cuschieri K, Wilson A, Patterson L, Govan L, Black J, Palmer T, Arbyn M.

Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1629-1635. doi: 10.1158/1055-9965.EPI-17-0534. Epub 2017 Sep 8.

22.

Pregnancy outcome after cervical conisation: A 2nd retrospective cohort study in the Leuven University Hospital.

van Velthoven K, Poppe W, Verschuere H, Arbyn M.

Eur J Obstet Gynecol Reprod Biol. 2017 Sep;216:224-231. doi: 10.1016/j.ejogrb.2017.06.043. Epub 2017 Jun 29.

PMID:
28822944
23.

Cytology versus HPV testing for cervical cancer screening in the general population.

Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, Schünemann H, Paraskevaidis E, Arbyn M.

Cochrane Database Syst Rev. 2017 Aug 10;8:CD008587. doi: 10.1002/14651858.CD008587.pub2. Review.

PMID:
28796882
24.

Impact of anaesthesia mode on evaluation of LEEP specimen dimensions.

Mercuzot A, Chevreau J, Sevestre H, Muszynski C, Arbyn M, Sergent F, Gondry J.

J Gynecol Obstet Hum Reprod. 2017 Apr;46(4):339-342. doi: 10.1016/j.jogoh.2016.12.006. Epub 2017 Jan 30.

PMID:
28643661
25.

Accuracy of combinations of visual inspection using acetic acid or lugol iodine to detect cervical precancer: a meta-analysis.

Catarino R, Schäfer S, Vassilakos P, Petignat P, Arbyn M.

BJOG. 2018 Apr;125(5):545-553. doi: 10.1111/1471-0528.14783. Epub 2017 Jul 26. Review.

PMID:
28603909
26.

Role of mucosal high-risk human papillomavirus types in head and neck cancers in central India.

Gheit T, Anantharaman D, Holzinger D, Alemany L, Tous S, Lucas E, Prabhu PR, Pawlita M, Ridder R, Rehm S, Bogers J, Maffini F, Chiocca S, Lloveras B, Kumar RV, Somanathan T, de Sanjosé S, Castellsagué X, Arbyn M, Brennan P, Sankaranarayanan R, Pillai MR, Gangane N, Tommasino M; HPV-AHEAD study group.

Int J Cancer. 2017 Jul 1;141(1):143-151. doi: 10.1002/ijc.30712. Epub 2017 Apr 19.

27.

HPV-based cervical cancer screening- facts, fiction, and misperceptions.

Wentzensen N, Arbyn M.

Prev Med. 2017 May;98:33-35. doi: 10.1016/j.ypmed.2016.12.040. Epub 2017 Feb 6.

28.

Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.

Latsuzbaia A, Hebette G, Fischer M, Arbyn M, Weyers S, Vielh P, Schmitt F, Mossong J.

Diagn Cytopathol. 2017 May;45(5):384-390. doi: 10.1002/dc.23678. Epub 2017 Mar 1.

PMID:
28247516
29.

Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test.

Kyrgiou M, Kalliala IE, Mitra A, Fotopoulou C, Ghaem-Maghami S, Martin-Hirsch PP, Cruickshank M, Arbyn M, Paraskevaidis E.

Cochrane Database Syst Rev. 2017 Jan 26;1:CD009836. doi: 10.1002/14651858.CD009836.pub2. Review.

30.

Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice.

Wentzensen N, Arbyn M, Berkhof J, Bower M, Canfell K, Einstein M, Farley C, Monsonego J, Franceschi S.

Int J Cancer. 2017 May 15;140(10):2192-2200. doi: 10.1002/ijc.30579. Epub 2017 Jan 11. Review.

31.

Harms of cervical cancer screening in the United States and the Netherlands.

Habbema D, Weinmann S, Arbyn M, Kamineni A, Williams AE, M C M de Kok I, van Kemenade F, Field TS, van Rosmalen J, Brown ML.

Int J Cancer. 2017 Mar 1;140(5):1215-1222. doi: 10.1002/ijc.30524.

32.

Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis.

Prigge ES, Arbyn M, von Knebel Doeberitz M, Reuschenbach M.

Int J Cancer. 2017 Mar 1;140(5):1186-1198. doi: 10.1002/ijc.30516. Epub 2016 Dec 2. Review.

33.

Enrolment of young women attending cervical cancer screening to survey effectiveness of HPV vaccination.

Arbyn M, Vanden Broeck D, Bogers J, Van Damme P, Temmerman M, Weyers S.

Cancer Epidemiol. 2016 Dec;45:178-179. doi: 10.1016/j.canep.2016.10.017. Epub 2016 Nov 12. No abstract available.

PMID:
27847177
34.

Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions: A Systematic Review and Meta-analysis.

Arbyn M, Xu L, Verdoodt F, Cuzick J, Szarewski A, Belinson JL, Wentzensen N, Gage JC, Khan MJ.

Ann Intern Med. 2017 Jan 17;166(2):118-127. doi: 10.7326/M15-2735. Epub 2016 Nov 15. Review.

PMID:
27842420
35.

ANOVA model for network meta-analysis of diagnostic test accuracy data.

Nyaga VN, Aerts M, Arbyn M.

Stat Methods Med Res. 2018 Jun;27(6):1766-1784. doi: 10.1177/0962280216669182. Epub 2016 Sep 20.

PMID:
27655805
36.

Immediate referral to colposcopy versus cytological surveillance for low-grade cervical cytological abnormalities in the absence of HPV test: A systematic review and a meta-analysis of the literature.

Kyrgiou M, Kalliala I, Mitra A, Ng KY, Raglan O, Fotopoulou C, Martin-Hirsch P, Paraskevaidis E, Arbyn M.

Int J Cancer. 2017 Jan 1;140(1):216-223. doi: 10.1002/ijc.30419. Epub 2016 Oct 12. Review.

37.

Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis.

Kyrgiou M, Athanasiou A, Paraskevaidi M, Mitra A, Kalliala I, Martin-Hirsch P, Arbyn M, Bennett P, Paraskevaidis E.

BMJ. 2016 Jul 28;354:i3633. doi: 10.1136/bmj.i3633. Review.

38.

Direct comparison of two vaginal self-sampling devices for the detection of human papillomavirus infections.

Jentschke M, Chen K, Arbyn M, Hertel B, Noskowicz M, Soergel P, Hillemanns P.

J Clin Virol. 2016 Sep;82:46-50. doi: 10.1016/j.jcv.2016.06.016. Epub 2016 Jun 28.

PMID:
27434147
39.

Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests).

Cuschieri K, Geraets D, Cuzick J, Cadman L, Moore C, Vanden Broeck D, Padalko E, Quint W, Arbyn M.

J Clin Microbiol. 2016 Sep;54(9):2337-42. doi: 10.1128/JCM.00897-16. Epub 2016 Jul 6.

40.

Correction for Geraets et al., Clinical Evaluation of a GP5+/6+-Based Luminex Assay Having Full High-Risk Human Papillomavirus Genotyping Capability and an Internal Control.

Geraets DT, Cuschieri K, de Koning MNC, van Doorn LJ, Snijders PJF, Meijer CJLM, Quint WGV, Arbyn M.

J Clin Microbiol. 2016 Jul;54(7):1927. doi: 10.1128/JCM.00753-16. No abstract available.

41.

Reply to HPV test results provide useful risk stratification information in women with ASC-H Pap test findings.

Arbyn M, Xu L, Wentzensen N.

Cancer Cytopathol. 2016 Oct;124(10):754-755. doi: 10.1002/cncy.21754. Epub 2016 Jun 23. No abstract available.

42.

Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework.

Heard I, Cuschieri K, Geraets DT, Quint W, Arbyn M.

J Clin Virol. 2016 Aug;81:6-11. doi: 10.1016/j.jcv.2016.05.004. Epub 2016 May 19.

PMID:
27262102
43.

Analytical performance evaluation of Anyplex II HPV28 and Euroarray HPV for genotyping of cervical samples.

Latsuzbaia A, Tapp J, Nguyen T, Fischer M, Arbyn M, Weyers S, Mossong J.

Diagn Microbiol Infect Dis. 2016 Jul;85(3):318-322. doi: 10.1016/j.diagmicrobio.2016.04.011. Epub 2016 Apr 19.

PMID:
27156793
44.

Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway-PaVDaG study).

Stanczuk G, Baxter G, Currie H, Lawrence J, Cuschieri K, Wilson A, Arbyn M.

BMJ Open. 2016 Apr 25;6(4):e010660. doi: 10.1136/bmjopen-2015-010660.

45.

Barriers and opportunities for return-to-work of cancer survivors: time for action--rapid review and expert consultation.

Kiasuwa Mbengi R, Otter R, Mortelmans K, Arbyn M, Van Oyen H, Bouland C, de Brouwer C.

Syst Rev. 2016 Feb 24;5:35. doi: 10.1186/s13643-016-0210-z. Review.

46.

Surveillance of effects of HPV vaccination in Belgium.

Arbyn M, Broeck DV, Benoy I, Bogers J, Depuydt C, Praet M, Sutter PD, Hoorens A, Hauben E, Poppe W, Van Ranst M, Delvenne P, Gofflot S, Pétein M, Engelen F, Vanneste A, Beeck LO, Damme PV, Temmerman M, Weyers S.

Cancer Epidemiol. 2016 Apr;41:152-8. doi: 10.1016/j.canep.2015.12.011. Epub 2016 Feb 16.

PMID:
26895623
47.

World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer.

Santesso N, Mustafa RA, Schünemann HJ, Arbyn M, Blumenthal PD, Cain J, Chirenje M, Denny L, De Vuyst H, Eckert LO, Forhan SE, Franco EL, Gage JC, Garcia F, Herrero R, Jeronimo J, Lu ER, Luciani S, Quek SC, Sankaranarayanan R, Tsu V, Broutet N; Guideline Support Group.

Int J Gynaecol Obstet. 2016 Mar;132(3):252-8. doi: 10.1016/j.ijgo.2015.07.038. Epub 2015 Dec 14.

PMID:
26868062
48.

Triage of HPV positive women in cervical cancer screening.

Wentzensen N, Schiffman M, Palmer T, Arbyn M.

J Clin Virol. 2016 Mar;76 Suppl 1:S49-S55. doi: 10.1016/j.jcv.2015.11.015. Epub 2015 Nov 28. Review.

49.

Triage of ASC-H: A meta-analysis of the accuracy of high-risk HPV testing and other markers to detect cervical precancer.

Xu L, Verdoodt F, Wentzensen N, Bergeron C, Arbyn M.

Cancer Cytopathol. 2016 Apr;124(4):261-72. doi: 10.1002/cncy.21661. Epub 2015 Nov 30. Review.

50.

HPV testing in the context of post-treatment follow up (test of cure).

Cuschieri K, Bhatia R, Cruickshank M, Hillemanns P, Arbyn M.

J Clin Virol. 2016 Mar;76 Suppl 1:S56-S61. doi: 10.1016/j.jcv.2015.10.008. Epub 2015 Oct 22. Review.

PMID:
26525202

Supplemental Content

Support Center